| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
186,103,000 |
| Market
Cap: |
6.95(B) |
| Last
Volume: |
2,045,732 |
Avg
Vol: |
1,014,771 |
| 52
Week Range: |
$7.36 - $65.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
7,861 |
33,039 |
122,069 |
555,462 |
| Total Sell Value |
$354,730 |
$1,293,514 |
$1,368,502 |
$1,859,762 |
| Total People Sold |
3 |
3 |
3 |
5 |
| Total Sell Transactions |
4 |
13 |
19 |
38 |
| End Date |
2025-11-02 |
2025-08-01 |
2025-01-31 |
2024-02-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2026-01-20 |
4 |
AS |
$35.67 |
$137,936 |
D/D |
(3,867) |
21,354 |
|
3% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
25,221 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2025-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
21,667 |
75,912 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-11-25 |
4 |
S |
$54.28 |
$62,802 |
D/D |
(1,157) |
18,971 |
|
42% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-11-25 |
4 |
S |
$54.28 |
$34,196 |
D/D |
(630) |
21,585 |
|
42% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-11-25 |
4 |
S |
$54.28 |
$119,796 |
D/D |
(2,207) |
54,245 |
|
42% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,666 |
20,128 |
|
- |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
1,903 |
22,215 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2025-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,110 |
56,452 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2025-09-09 |
4 |
AS |
$45.16 |
$311,214 |
D/D |
(6,666) |
49,342 |
|
-22% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-09-05 |
4 |
AS |
$37.87 |
$256,851 |
D/D |
(6,666) |
56,008 |
|
-10% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-09-04 |
4 |
AS |
$32.43 |
$57,693 |
D/D |
(1,721) |
17,462 |
|
2% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-09-04 |
4 |
AS |
$32.37 |
$174,108 |
D/D |
(5,166) |
62,674 |
|
2% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-09-02 |
4 |
AS |
$30.16 |
$45,240 |
D/D |
(1,500) |
67,840 |
|
37% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-09-02 |
4 |
AS |
$30.10 |
$14,599 |
D/D |
(485) |
19,183 |
|
37% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-08-19 |
4 |
S |
$26.59 |
$17,975 |
D/D |
(676) |
20,312 |
|
-67% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-08-19 |
4 |
S |
$26.59 |
$41,826 |
D/D |
(1,573) |
69,340 |
|
-67% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-08-19 |
4 |
S |
$26.59 |
$19,278 |
D/D |
(725) |
19,668 |
|
-67% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-05-19 |
4 |
S |
$0.67 |
$6,697 |
D/D |
(9,996) |
314,296 |
|
-461% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-05-19 |
4 |
S |
$0.67 |
$7,177 |
D/D |
(10,712) |
305,892 |
|
-461% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-05-19 |
4 |
S |
$0.67 |
$15,549 |
D/D |
(23,208) |
1,063,693 |
|
-461% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-02-19 |
4 |
S |
$1.01 |
$10,403 |
D/D |
(10,300) |
316,604 |
|
-72% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-02-19 |
4 |
S |
$1.01 |
$11,150 |
D/D |
(11,040) |
324,292 |
|
-72% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-02-19 |
4 |
S |
$1.01 |
$24,012 |
D/D |
(23,774) |
1,086,901 |
|
-72% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-12-24 |
4 |
S |
$0.89 |
$14,738 |
D/D |
(16,560) |
335,332 |
|
33% |
|
665 Records found
|
|
Page 1 of 27 |
|
|
2.10 (5.96%) 
